OCUL
Price
$12.81
Change
+$0.04 (+0.31%)
Updated
Sep 12, 04:59 PM (EDT)
Capitalization
2.23B
59 days until earnings call
ZVRA
Price
$7.74
Change
-$0.21 (-2.64%)
Updated
Sep 12, 04:59 PM (EDT)
Capitalization
446.27M
54 days until earnings call
Interact to see
Advertisement

OCUL vs ZVRA

Header iconOCUL vs ZVRA Comparison
Open Charts OCUL vs ZVRABanner chart's image
Ocular Therapeutix
Price$12.81
Change+$0.04 (+0.31%)
Volume$51.35K
Capitalization2.23B
Zevra Therapeutics
Price$7.74
Change-$0.21 (-2.64%)
Volume$33.41K
Capitalization446.27M
OCUL vs ZVRA Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. ZVRA commentary
Sep 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 13, 2025
Stock price -- (OCUL: $12.77 vs. ZVRA: $7.95)
Brand notoriety: OCUL and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 56% vs. ZVRA: 93%
Market capitalization -- OCUL: $2.22B vs. ZVRA: $446.27M
OCUL [@Biotechnology] is valued at $2.22B. ZVRA’s [@Biotechnology] market capitalization is $446.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.88B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, both OCUL and ZVRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • OCUL’s TA Score: 3 bullish, 5 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +0.55% price change this week, while ZVRA (@Biotechnology) price change was -10.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.44%. For the same industry, the average monthly price growth was +8.10%, and the average quarterly price growth was +35.54%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.23B) has a higher market cap than ZVRA($446M). OCUL YTD gains are higher at: 50.000 vs. ZVRA (-7.074). ZVRA has higher annual earnings (EBITDA): 36.4M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. ZVRA (203M). ZVRA has less debt than OCUL: ZVRA (62.3M) vs OCUL (76.9M). ZVRA has higher revenues than OCUL: ZVRA (62M) vs OCUL (56.7M).
OCULZVRAOCUL / ZVRA
Capitalization2.23B446M500%
EBITDA-200.5M36.4M-551%
Gain YTD50.000-7.074-707%
P/E RatioN/AN/A-
Revenue56.7M62M91%
Total Cash391M203M193%
Total Debt76.9M62.3M123%
FUNDAMENTALS RATINGS
OCUL vs ZVRA: Fundamental Ratings
OCUL
ZVRA
OUTLOOK RATING
1..100
1554
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
81100
SMR RATING
1..100
9888
PRICE GROWTH RATING
1..100
3965
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (54) in the Pharmaceuticals Other industry is in the same range as ZVRA (78) in the null industry. This means that OCUL’s stock grew similarly to ZVRA’s over the last 12 months.

OCUL's Profit vs Risk Rating (81) in the Pharmaceuticals Other industry is in the same range as ZVRA (100) in the null industry. This means that OCUL’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's SMR Rating (88) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that ZVRA’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as ZVRA (65) in the null industry. This means that OCUL’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (25) in the null industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that ZVRA’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULZVRA
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 24 days ago
85%
Bearish Trend 2 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AQEAX16.13N/A
N/A
Columbia Disciplined Core A
CMRAX10.68N/A
N/A
Calamos Merger Arbitrage A
TFOAX82.37N/A
N/A
Touchstone Focused A
MKSPX31.47N/A
N/A
BlackRock Advantage SMID Cap K
MDVWX8.22N/A
N/A
Manning & Napier Disciplined Value W

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.31%
EYPT - OCUL
65%
Loosely correlated
+0.15%
IDYA - OCUL
55%
Loosely correlated
-1.28%
RVMD - OCUL
55%
Loosely correlated
+0.67%
CRNX - OCUL
55%
Loosely correlated
+0.80%
NRIX - OCUL
55%
Loosely correlated
-1.74%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with ACLX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
-2.52%
ACLX - ZVRA
35%
Loosely correlated
-1.92%
IMTX - ZVRA
35%
Loosely correlated
-1.69%
COGT - ZVRA
34%
Loosely correlated
-1.17%
ATXS - ZVRA
34%
Loosely correlated
-5.23%
OCUL - ZVRA
33%
Loosely correlated
+0.31%
More